LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2016.
“Concert has made significant progress with our pipeline of multiple products, including CTP-656 and CTP-543, both of which we are committed to advancing into efficacy trials in 2017. CTP-656 for cystic fibrosis has demonstrated properties that we believe will be beneficial over the current standard of care. CTP-543 for alopecia areata is following a similar approach of building on the known activity of approved drugs to provide a novel and differentiated treatment for patients,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals, Inc. “These drug candidates demonstrate the ability of our DCE Platform® to readily bring new drug candidates into development with the potential to improve patient care, whether competing with the non-deuterated drug in an existing market or meeting an unmet need in a new market.”
“Concert has made significant progress with our pipeline of multiple products, including CTP-656 and CTP-543, both of which we are committed to advancing into efficacy trials in 2017. CTP-656 for cystic fibrosis has demonstrated properties that we believe will be beneficial over the current standard of care. CTP-543 for alopecia areata is following a similar approach of building on the known activity of approved drugs to provide a novel and differentiated treatment for patients,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals, Inc. “These drug candidates demonstrate the ability of our DCE Platform® to readily bring new drug candidates into development with the potential to improve patient care, whether competing with the non-deuterated drug in an existing market or meeting an unmet need in a new market.”
